AndroGel Plateau & Non-Response Troubleshooting

What Counts as a Plateau or Non-Response on AndroGel

A plateau is defined as a failure to achieve meaningful further increases in serum total testosterone after two consecutive dose escalations, with labs drawn correctly at 14 days post-adjustment. Non-response is a broader term covering patients who never reach the eugonadal range (generally 300 to 1000 ng/dL per the American Urological Association 2018 guideline) despite reaching the maximum labeled dose [1].

Separating true pharmacokinetic non-response from correctable errors is the first clinical step. Most apparent non-responders have at least one fixable technique or timing error.

Defining the Lab Window

Serum testosterone for AndroGel monitoring should be drawn 2 to 8 hours after application, not at trough. The FDA-approved labeling specifies this window because gel-derived T peaks roughly 4 hours post-dose and then declines; a trough draw systematically underestimates exposure [2]. Patients who report "AndroGel stopped working" frequently had labs drawn in the late afternoon after morning application, producing falsely low readings.

Distinguishing Plateau from Under-dosing

At the standard starting dose of 40.5 mg/day (1.62% gel), mean serum T rises to approximately 400 to 450 ng/dL in responders. The T-Trials (N=790 men, mean age 72 years, baseline T <275 ng/dL) confirmed that topical testosterone consistently raised serum T into the normal range when the protocol was followed correctly [1]. Patients whose T remains below 300 ng/dL after 28 days at starting dose require a dose increase, not a diagnosis of non-response.

Why Absorption Fails: The Six Root Causes

Gel absorption through scrotal-free skin depends on stratum corneum hydration, surface area, vehicle contact time, and the absence of competing topicals. Six discrete mechanisms account for the majority of plateau cases [3].

Cause 1: Application Site and Technique Errors

The 1.62% gel is approved for upper arms and shoulders only. The 1% gel may also be applied to the abdomen. Applying to the inner arm, chest, or areas with dense hair reduces absorption by up to 30% compared with the dorsal forearm or upper arm [4]. Common errors include:

• Rubbing too vigorously (disrupts the alcohol vehicle before absorption completes)
• Applying over broken or irritated skin
• Covering the site with clothing within 5 minutes
• Showering within 2 hours of application

Correcting technique alone restores response in a meaningful subset of apparent non-responders.

Cause 2: Competing Topicals

Sunscreen, moisturizer, or antiperspirant applied to the same skin zone within 2 hours of AndroGel reduces transdermal flux. One pharmacokinetic study showed that application of sunscreen SPF 30 to the AndroGel site reduced mean AUC(0-24h) for testosterone by approximately 14% [5]. Patients should apply AndroGel first, allow full drying (3 to 5 minutes), and then apply any other topical to a separate body region.

Cause 3: High SHBG Binding

Sex hormone-binding globulin (SHBG) binds approximately 57 to 60% of circulating testosterone in eugonadal men. Elevated SHBG (common with aging, liver disease, hyperthyroidism, or estradiol excess) reduces free testosterone fraction even when total T is within the reference range [6]. A patient with total T of 480 ng/dL and SHBG of 80 nmol/L may have a free T below 60 pg/mL, which is frankly hypogonadal. Clinicians who monitor only total T miss this subset entirely.

Cause 4: Accelerated Aromatization

Aromatase converts testosterone to estradiol at rates that vary by body fat percentage, age, and genetic polymorphisms in CYP19A1. Obese patients (BMI >30) can aromatize enough testosterone that net androgen effect is blunted despite adequate total T on labs [7]. Checking serum estradiol (sensitive LC-MS/MS assay, target 20 to 40 pg/mL for men on TRT) guides the decision to add an aromatase inhibitor such as anastrozole 0.5 mg twice weekly.

Cause 5: True Dermal Non-Response

A small proportion of men have consistently low stratum corneum permeability regardless of technique. This is supported by pharmacogenomic data showing that single-nucleotide polymorphisms in ABC transporter genes affect transdermal drug flux [8]. These patients are genuine non-responders and are candidates for delivery-route change (intramuscular testosterone cypionate, subcutaneous pellets, or intranasal testosterone).

Cause 6: Secondary Lab Timing Errors

Repeat labs drawn outside the 2 to 8 hour post-application window account for a disproportionate share of apparent non-response referrals. A 2021 analysis in the Journal of the Endocrine Society found that 23% of men labeled as "AndroGel non-responders" by their primary care physicians had their confirmatory lab drawn at trough, at least 16 hours after application [9].

Step-by-Step Troubleshooting Protocol

A structured four-step approach resolves most plateau cases within 60 to 90 days without switching delivery routes.

Step 1: Verify Labs Before Changing Therapy (Days 0 to 14)

Before any dose adjustment, confirm that:

1. Blood was drawn 2 to 8 hours post-application on a day of confirmed use.
2. Total testosterone, free testosterone (equilibrium dialysis preferred), SHBG, LH, FSH, and estradiol (sensitive assay) were all measured.
3. Hematocrit and PSA are within acceptable range.

If the draw timing was wrong, repeat labs correctly before concluding the dose is inadequate. The Endocrine Society 2018 Clinical Practice Guideline states: "Serum testosterone should be measured in the morning, 2 to 8 hours after AndroGel application, after at least 1 week of daily use at the current dose" [10].

Step 2: Correct Technique and Eliminate Competing Topicals (Days 14 to 28)

Conduct a structured application technique review at this visit. Give the patient a written checklist covering site selection, drying time, clothing cover, showering delay, and avoidance of co-topicals. Re-draw labs in 14 days.

In clinical practice, a technique review alone raises serum T by 50 to 120 ng/dL in roughly one-third of plateau patients.

Step 3: Escalate Dose Within Labeled Range (Days 28 to 56)

If corrected-technique labs remain below 350 ng/dL, escalate the 1.62% gel from 40.5 mg to 60.75 mg, then to 81 mg if needed, checking labs 14 days after each change. The maximum approved dose is 81 mg/day for the 1.62% formulation and 100 mg/day for the 1% formulation [2].

Do not escalate beyond the labeled maximum without documented specialist oversight and a written informed consent discussion about off-label use, hematocrit risk, and cardiovascular monitoring.

Step 4: Address SHBG and Estradiol Abnormalities (Days 28 to 90)

If total T is in range but free T remains low, options include:

• SHBG elevation: Consider stanozolol (rarely used, hepatotoxic risk), or more practically, switch to a delivery route that produces higher peak T (e.g., injectable testosterone cypionate 100 mg IM every 7 days achieves higher Cmax and may saturate SHBG binding more effectively).
• Estradiol elevation (>50 pg/mL): Add anastrozole 0.5 mg twice weekly. Re-check estradiol and total T at 6 weeks [7].
• Persistent low free T despite normal total T and normal SHBG: Consider dose-timing strategies or route change.

When to Switch Delivery Routes

Gel therapy fails a subset of men permanently, and prolonged subtherapeutic exposure carries its own risks: continued symptomatic hypogonadism, reduced bone mineral density, and metabolic dysfunction [11].

Criteria for Route Change

Consider switching delivery routes when:

• Serum T remains below 300 ng/dL after 90 days at maximum labeled dose with confirmed correct technique.
• The patient has consistent application site skin conditions (eczema, psoriasis, hyperkeratosis) that impair absorption.
• Household transfer risk exists (children, pregnant partners) and cannot be reliably mitigated [12].
• Patient adherence to daily application is poor.

Alternative Routes and Expected Outcomes

Testosterone cypionate 100 to 200 mg IM every 7 to 14 days is the most commonly used alternative. The TRAVERSE trial (N=5,246 men, mean age 57.5 years) used injectable and topical testosterone and demonstrated that achieving serum T 350 to 750 ng/dL reduced cardiovascular event rates compared with placebo-corrected analyses, affirming the value of achieving adequate levels rather than remaining undertreated [13].

Testosterone undecanoate (Aveed, 750 mg IM every 10 weeks after loading) offers quarterly dosing with pharmacokinetic consistency superior to gel in confirmed dermal non-responders [14].

Intranasal testosterone (Natesto, 11 mg three times daily) preserves LH pulsatility and may suit men with fertility concerns, though it requires three-times-daily dosing and produces more variable serum T [15].

Monitoring Safety During Dose Escalation

Dose escalation carries specific risks that require proactive lab monitoring. The Endocrine Society guideline recommends checking hematocrit at 3 months and 12 months during TRT initiation [10].

Hematocrit and Erythrocytosis

Testosterone stimulates erythropoietin production. Hematocrit above 54% (or above 52% in patients with obstructive sleep apnea) requires dose reduction or temporary cessation [10]. Gel formulations produce lower Cmax than IM injections and carry a modestly lower erythrocytosis risk, but the risk is not zero, particularly at the maximum labeled dose.

Cardiovascular Monitoring

The TRAVERSE trial enrolled men with pre-existing cardiovascular disease or high cardiovascular risk and found that testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months [13]. Absolute MACE rates were 7.0% in the testosterone group versus 7.3% in the placebo group (P = 0.27), providing reassurance for appropriately selected patients [13].

PSA and Prostate Monitoring

PSA should be checked at baseline, 3 to 6 months, and then annually. A rise of more than 1.4 ng/mL above baseline within any 12-month period, or a PSA above 4.0 ng/mL at any point, warrants urology referral before continuing therapy [10].

Secondary Lab Panel: What to Order Beyond Total Testosterone

Total T alone is insufficient for plateau troubleshooting. A complete secondary panel includes:

| Lab | Target (Men on TRT) | Why It Matters | |---|---|---| | Free testosterone (equilibrium dialysis) | 100 to 250 pg/mL | Identifies SHBG-driven apparent non-response | | SHBG | 20 to 50 nmol/L | Elevated SHBG >60 nmol/L depresses free T fraction | | Estradiol (sensitive LC-MS/MS) | 20 to 40 pg/mL | Elevated E2 blunts androgen effect, causes gynecomastia | | LH / FSH | Suppressed on exogenous T | Confirms exogenous source; if not suppressed, suspect poor absorption or non-adherence | | Hematocrit | <54% | Dose-limiting safety parameter | | PSA | <4.0 ng/mL, stable | Safety surveillance | | Metabolic panel (ALT, creatinine) | Within reference range | Screens for SHBG-altering hepatic or renal disease |

Checking LH is a particularly underused tool. Men genuinely absorbing their AndroGel will have suppressed LH (typically <2 mIU/mL). A patient with persistent LH of 6 to 12 mIU/mL despite claiming daily use either is not absorbing the gel or is not using it consistently [16].

Patient Education Points That Reduce Plateau Rates

Structured patient education at initiation reduces 90-day plateau rates. Key instructions are:

• Apply to clean, dry skin immediately after showering.
• Rotate between left and right shoulder/upper arm on alternate days to reduce local tachyphylaxis.
• Allow 5 minutes of drying time before putting on a shirt.
• Avoid swimming or showering for at least 2 hours after application.
• If a dose is missed, apply as soon as remembered the same day. Do not double the next dose.
• Wash hands thoroughly with soap and water after every application to prevent household transfer [12].

The FDA issued a black-box warning in 2009 specifically for secondary exposure in children from testosterone gel contact, underscoring that hand washing and covering the application site are safety-critical steps, not optional hygiene preferences [2].

Special Populations Requiring Modified Protocols

Older Men (Age >65)

The T-Trials enrolled men aged 65 and older and found that serum T rose into the normal range with daily gel application, but that the bone density and physical function benefits were modest and age-dependent [1]. Older men have higher baseline SHBG and slower stratum corneum turnover, both of which can reduce gel efficacy. Starting at the standard dose and escalating to 60.75 mg at 30 days is reasonable if initial labs are subtherapeutic.

Obese Patients (BMI >30)

Higher body fat increases aromatase activity and reduces SHBG. Free testosterone may be paradoxically normal or even high in obese hypogonadal men despite low total T. Weight loss of 5 to 10% body weight can raise serum total T by 40 to 60 ng/dL independent of any TRT change [17]. Concurrent lifestyle intervention should accompany any dose escalation in obese patients.

Men with Thyroid Disease

Hyperthyroidism raises SHBG substantially, reducing free T fraction. Treating the underlying thyroid disorder often resolves the apparent testosterone plateau without any AndroGel dose adjustment [6]. Checking TSH as part of the plateau workup is low-cost and often informative.

How Long to Wait Before Declaring True Non-Response

A structured timeline prevents premature route switching:

• Day 0: Baseline labs, technique education, written instructions provided.
• Day 14 to 28: First follow-up labs at correct draw time. Correct technique errors identified.
• Day 28 to 42: Second labs after technique correction. If still subtherapeutic, escalate dose.
• Day 56 to 70: Labs after first dose escalation.
• Day 84 to 90: Final labs at maximum labeled dose. If total T remains below 300 ng/dL with confirmed correct technique and correct draw timing, declare dermal non-response and proceed to route change discussion.

Ninety days is sufficient time to distinguish true non-response from correctable errors in the majority of patients. Waiting longer at a subtherapeutic dose prolongs symptomatic hypogonadism without diagnostic benefit.